Source:http://linkedlifedata.com/resource/pubmed/id/20346427
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2010-9-13
|
pubmed:abstractText |
The identification of proteins aberrantly expressed in malignant B-cells can potentially be used to develop new diagnostic, prognostic or therapeutic targets. Proteomic studies of B-cell malignancies have made significant progress, but further studies are needed to increase our coverage of the B-cell malignant proteome. To achieve this goal we stress the advantages of using sub-cellular fractionation, protein separation, quantitation and affinity purification techniques to identify hitherto unidentified signalling and regulatory proteins. For example, proteomic analysis of B-cell plasma membranes isolated from patients with mantle cell lymphoma (MCL) identified the voltage-gated proton channel (HVCN1,[1]). This protein has now been characterised as a key modulator of B-cell receptor (BCR) signalling and abrogation of HVCN1 function could have a role in the treatment of B-cell malignancies dependent on maintained BCR signalling [2]. Similarly, proteomic studies on cell lysates from prognostic subtypes of CLL, distinguished by the absence (UM-CLL) or presence (M-CLL) of somatic hypermutation of the immunoglobulin heavy chain locus identified nucleophosmin 1 (NMP1) as a potential prognostic marker [3,4]. Thus, targeted proteomic analysis on selected organelles or sub-cellular compartments can identify novel proteins with unexpected localisation or function in malignant B-cells that could be developed for clinical purposes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1876-7737
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2010 Elsevier B.V. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
10
|
pubmed:volume |
73
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1804-22
|
pubmed:meshHeading |
pubmed-meshheading:20346427-B-Lymphocytes,
pubmed-meshheading:20346427-Cell Fractionation,
pubmed-meshheading:20346427-Electrophoresis, Gel, Two-Dimensional,
pubmed-meshheading:20346427-Humans,
pubmed-meshheading:20346427-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:20346427-Lymphoma, B-Cell,
pubmed-meshheading:20346427-Lymphoma, Mantle-Cell,
pubmed-meshheading:20346427-Membrane Microdomains,
pubmed-meshheading:20346427-Phosphoproteins,
pubmed-meshheading:20346427-Proteomics,
pubmed-meshheading:20346427-Tumor Markers, Biological
|
pubmed:year |
2010
|
pubmed:articleTitle |
Proteomic analysis of B-cell malignancies.
|
pubmed:affiliation |
MRC Toxicology Unit, Hodgkin Building, Lancaster Rd, University of Leicester, Leicester, LE1 9HN, UK.
|
pubmed:publicationType |
Journal Article,
Review
|